Sermorelin
Sermorelin (GRF 1-29) acts as the fundamental bioidentical analog of naturally occurring Growth Hormone-Releasing Hormone (GHRH). Originally developed as an FDA-approved diagnostic agent (Geref), it has become the bedrock of clinical anti-aging endocrinology. Unlike synthetic secretagogues (like GHRPs) that force unnatural spikes via the ghrelin pathway, Sermorelin exclusively orchestrates physiological, pulsatile Growth Hormone release. It is typically prescribed to safely restore youthful IGF-1 baseline levels, drastically improve slow-wave sleep architecture, and accelerate lean tissue recovery without the side effects of exogenous hGH therapy.
Quick Stats
Scientific Data
Mechanism of Action
Sermorelin (GRF 1-29) is a bioidentical analog of natural Growth Hormone Releasing Hormone (GHRH), consisting of the first 29 amino acids of the 44-amino-acid GHRH peptide. These 29 amino acids contain the full biological activity of the complete molecule.
Sermorelin stimulates pituitary somatotroph cells to produce and release growth hormone in a pulsatile, physiological pattern. Unlike exogenous HGH administration, Sermorelin preserves the negative feedback loop — the body still regulates GH output, making supraphysiological levels unlikely. This makes it the safest long-term GH-enhancing option in clinical medicine. FDA-approved as Geref for diagnostic use.
Source: PMID: 9677584
Background & History
Sermorelin (GHRH 1-29 NH₂) is the first 29 amino acids of endogenous GHRH and was the first GHRH analog to receive FDA approval (1997, as Geref, for pediatric GH deficiency). It was developed by researchers at Salk Institute and commercialized by Serono. Unlike CJC-1295 no-DAC with its four protective substitutions, sermorelin is the unmodified sequence and degrades faster (~10-20 min half-life). It was the gold standard for GH stimulation testing before GHRH analogs with better stability were developed.
Research Use Cases
- ✓Adult GH deficiency: anti-aging and body composition
- ✓Pediatric growth failure diagnosis and treatment (historical FDA use)
- ✓Mild GH stimulation protocols with lower side effect profile
- ✓Sleep improvement and recovery enhancement
Dosing Protocol
| Typical Dose | 200-300 mcg/day |
| Frequency | 1× daily (before bed) |
| Half-Life | ~10-20 minutes |
| Common Vial Sizes | 2 mg, 5 mg, 9 mg |
Dosing Protocols
Starting / Clinical
Standard Stack
Body-Weight Dosing Reference
Estimated doses extrapolated from the published research range of 200–300 mcg/day (referenced to 70 kg / 154 lb). These are approximations — consult a qualified healthcare provider for personalised guidance.
| Weight | Low Dose | Target Dose | High Dose |
|---|---|---|---|
| 120 lb(54 kg) | 154 mcg | 193 mcg | 231 mcg |
| 140 lb(63 kg) | 180 mcg | 225 mcg | 270 mcg |
| 160 lb(73 kg) | 209 mcg | 261 mcg | 313 mcg |
| 180 lb(82 kg) | 234 mcg | 293 mcg | 351 mcg |
| 200 lb(91 kg) | 260 mcg | 325 mcg | 390 mcg |
| 220 lb(100 kg) | 286 mcg | 357 mcg | 429 mcg |
| 250 lb(113 kg) | 323 mcg | 404 mcg | 484 mcg |
💉 For exact syringe units based on your vial concentration, use the Sermorelin Reconstitution Calculator →
Administration
Expected Timeline
Who Is It For?
GH Optimization / Anti-Aging
HighFDA-approved with decades of clinical use. Preserves the pituitary feedback loop unlike direct HGH.
Body Composition
ModerateImproves lean mass and fat distribution over 3-6 months of consistent use.
Sleep Quality
ModerateAmplifies the natural nocturnal GH pulse, improving deep sleep and recovery.
Reconstitution Example
Safety & Considerations
FDA-approved (Geref) with decades of clinical safety data. Common side effects: injection site flushing and mild headache. Preserves pituitary feedback — far safer than exogenous HGH for long-term use.
Regulatory & Legal Status
Former FDA approval withdrawn; available in US via licensed compounding pharmacies
Competitive athletes subject to anti-doping controls should not use Sermorelin.
Compounded Drug (Rx)
US Compounding: Available via licensed pharmacy Rx
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Interactions & Contraindications
Same GH-class interactions as other GHRH analogs: monitor blood glucose, avoid with active cancer. Glucocorticoids blunt GH response.
Synergies & Common Stacks
Sermorelin + Ipamorelin provides GHRH+GHRP synergy similar to Mod GRF + Ipamorelin but with slightly shorter action. Popular combination in anti-aging wellness clinics.
Sermorelin vs. Tesamorelin
| Attribute | Sermorelin | Tesamorelin |
|---|---|---|
| FDA Status | Not FDA-approved (was revoked) | FDA-approved (Egrifta® — HIV lipodystrophy) |
| Half-Life | ~11–13 minutes | ~26 minutes (longer-acting) |
| Potency | Moderate GH stimulation | Stronger — more potent GHRH analog |
| Best For | General GH/IGF-1 anti-aging protocol | Visceral fat reduction (clinical + wellness) |
| WADA Status | Prohibited (S2) | Prohibited (S2) |
| Availability | Compounded pharmacy (Rx) | Branded Rx + compounded |
Verdict: Tesamorelin is the more potent and clinically validated GHRH analog with FDA approval for lipodystrophy. Sermorelin is more widely compounded and used for general anti-aging GH optimization at lower cost.
Dosing Quick Reference
Frequently Asked Questions
Why is Sermorelin preferred over HGH?▼
What is the best time to inject Sermorelin?▼
Can Sermorelin be combined with Ipamorelin?▼
References
- Walker RF “"Sermorelin: a better approach to management of adult-onset GH insufficiency?".” Clinical Interventions in Aging (2006). PMID: 18046879
📚 Related Articles
Get Sermorelin from our recommended source — independently tested, COA-verified, USP <85> endotoxin compliant. Use code 4SS6SFTUGB at checkout.
Affiliate link · Full review